We found that IS signaling was significantly impaired in our patients with MetS, as confirmed by significantly reduced molecular concentrations serine/tyrosine-kinase mTOR (p < 0.05 vs control) and its downstream effectors p70S6K1 and p-4E-BP1 (respectively: p < 0.02 and p < 0.05 vs controls). The gene discussed is EIF4EBP1; the disease is metabolic syndrome.